江苏威奇达药业有限公司（原名上海现代制药海门有限公司）于2010年2月在江苏省南通市成立，隶属于上海现代制药股份有限公司（以下简称国药现代），注册资本人民币8亿元，2020年9月更名为江苏威奇达药业有限公司。

Jiangsu Weiqida Pharmaceutical Co., Ltd. (formerly known as Shanghai Shyndec Pharmaceutical Haimen Co., Ltd.) was established in Feb.,2010 in Nantong City,Jiangsu Province,under Shanghai Shyndec Pharmaceutical Co.,Ltd. ,with a registered capital of 800 million yuan.

公司设有研发/技术中心，依托中国医药集团有限公司旗下中国医药工业研究总院有限公司，拥有强大的研发技术、专业的人才团队和先进的设备仪器，重点发展高技术含量、高附加值、低排放的特色原料药，致力于为国药现代（股票代码：600420）重点大品种、潜力品种及新立项产品提供相应的原料药、中间体配套供应，同时为国内外企业提供CDMO定制项目，打造成为集化学原料药生产及中间体的研发中试和定制加工、大健康产品研发生产为一体的综合型医药生产企业。公司主要产品涵盖抗感染类、心血管类、大健康类等领域，产品覆盖20多个国家和地区。

The company has a R&D Technology Center, relying on the China State Institute of Pharmaceutical Industry under the China National Pharmaceutical Group, with strong R&D technology, professional talent team and advanced equipment and instruments.The company focuses on the development of high-tech, high-value-added, low-emission characteristics APIs, is committed to provide the corresponding APIs, intermediates of the main large varieties, potential varieties and new projects of the Shanghai Shyndec(Stock Code 600420)and provide CDMO customized projects for domestic and foreign enterprises,to build a set of chemical raw materials and intermediates production and R&D pilot and customized processing, research and development and production of health products as one of the integrated pharmaceutical production enterprises.The main products cover the fields of anti-infectives, cardiovascular ,and general health.The products cover more than 20 countries .

公司致力于成为专业、服务、创新、可靠的制药服务平台，关爱生命，呵护健康。通过多年的沉淀，拥有完备的生产技术能力、完善的质量管理、EHS管理体系，能够为全球客户提供从中试放大到商业化生产的核心服务和各种认证注册申报支持。公司已先后通过NMPA、FDA、WHO等权威认证，可以为全球知名药企提供长期服务。

The company is committed to become a professional, service, innovative and reliable pharmaceutical service platform. “All for health, Health for all”. Through years of precipitation, we have complete production technology capabilities, perfect quality management, and EHS management systems,and have the ability to provide global customers with core services from pilot scale-up to commercial production and various certifications and registration declaration support. providing core services from pilot scale-up to commercial production and various certification, registration support.We have successively passed NMPA, FDA, WHO and other authoritative certifications, and can provide long-term services for world-renowned pharmaceutical companies.